Aldeyra Therapeutics Logo
US01438T1060
A111X8
ALDX

Aldeyra Therapeutics

A carregar cotações...

Previsão

O preço-alvo médio dos analistas é € 8,81 (+1.298,41%). A mediana é € 9,11 (+1.346,03%).

Comprar
  18
Manter
  1
Vender
  0

Discussões na comunidade

Ainda não há nenhuma discussão sobre este ativo.

Iniciar discussão

  • Aldeyra adds Darlene Deptula-Hicks to board of directors

    Aldeyra has appointed Darlene Deptula-Hicks to its board of directors; she brings more than 30 years of experience in the biotech sector and expertise as a finance executive at public and private life-science companies. Deptula-Hicks is currently interim CFO of Normunity and was previously CFO of F-star Therapeutics; her experience with IPOs, capital raising and M&A is expected to support potential commercialization of Aldeyra’s therapies. Aldeyra is developing RASP modulators and is advancing reproxalap and ADX-2191 in late-stage development; the company has a market capitalization of $104 million, a current ratio of 2.72, and its stock has traded well below last year’s level since the start of the year, while analyst price targets remain between $2 and $13. » Mais em de.investing.com


  • Aldeyra Therapeutics repays $15 million loan and terminates credit facility

    Aldeyra Therapeutics repaid all outstanding liabilities of $15 million on April 1, thereby terminating the loan agreement with Hercules Capital in accordance with the contract. The company reports a balance sheet with more cash than debt and expects that cash, cash equivalents and marketable securities will fund operations through 2028. At the same time, Aldeyra faces regulatory pressure following an FDA Complete Response Letter for Reproxalap; analyst reactions are mixed (BTIG: buy, price target $9.00; H.C. Wainwright: neutral, price target $2.00). The stock trades well below last year’s level, reflecting the ongoing uncertainties. » Mais em de.investing.com


  • Aldeyra Therapeutics: chief development officer Dr. Stephen G. Machatha to resign by March 2026

    Aldeyra Therapeutics announced that Dr. Stephen G. Machatha has voluntarily resigned as chief development officer; his last day will be no later than March 31, 2026. The company and Machatha reached a transition agreement under which he will remain employed through his departure, continue to receive his base salary and benefits, and have outstanding equity awards remain unchanged. As part of the agreement, Machatha will receive a one‑time payment of $88,000 and may receive an additional $88,000 if he signs further release agreements after leaving. The company emphasized that the resignation is not the result of any disagreement with management or the board. » Mais em de.investing.com


  • Aldeyra receives EMA orphan drug status for ADX-2191 to treat rare retinal diseases

    Aldeyra Therapeutics has been granted orphan drug status by the European Medicines Agency for ADX-2191 for the treatment of inherited retinal dystrophies, including retinitis pigmentosa. The company will benefit from regulatory advantages and plans to conduct further clinical trials, while its financial position is described as solid. Additionally, progress has been reported in the development and approval applications of other medications. » Mais em de.investing.com


  • Aldeyra receives positive FDA feedback for eye drug Reproxalap

    Aldeyra Therapeutics has announced that the US Food and Drug Administration (FDA) has accepted the resubmitted approval application for its eye drug Reproxalap, intended for the treatment of dry eye disease. The FDA's decision is expected by December 16, 2025, following the submission of additional clinical data. Analysts remain optimistic about the stock, and the company is financially well positioned to continue its development programs. » Mais em de.investing.com

Dados financeiros da empresa

No último trimestre, Aldeyra Therapeutics registou receitas de € 0 e um ganho líquido de -€ 3,32 mi
(EUR) setembro de 2026
YoY
Receitas 0 -
Ganho bruto 0 -
Ganho líquido -3,32 mi 49,29%
EBITDA -3,19 mi 47,71%

Dados fundamentais

Métrica Valor
Capitalização bolsista
€ 38,23 mi
Número de ações
60,36 mi
Máximo/mínimo de 52 semanas
€ 5,40 - € 0,48
Dividendos Não
Beta
1,29
PER (PE Ratio)
-2,18
PEG (PEG Ratio)
-0,02
P/VC (PB Ratio)
0,00
P/V (PS Ratio)
0,00

Perfil da empresa

A Aldeyra Therapeutics, Inc., uma empresa de biotecnologia, desenvolve e comercializa medicamentos para doenças oculares e sistémicas de mediação imunitária. O principal candidato a medicamento da empresa é o reproxalap, um modulador de espécies aldeídicas reativas (RASP), que se encontra em ensaio clínico de Fase III para o tratamento da síndrome do olho seco e da conjuntivite alérgica. A empresa desenvolve também o ADX-629, um modulador RASP de primeira classe, de administração oral, que se encontra em ensaio clínico de Fase II para a psoríase, a asma e a COVID-19; e o ADX-2191, um inibidor da di-hidrofolato redutase, que se encontra na fase 3 para a prevenção da vitreorretinopatia proliferativa, e na fase II de ensaio clínico para o tratamento da retinose pigmentar, bem como para o tratamento do linfoma vitreorretiniano primário. A empresa tem um acordo de licença com a Madrigal Pharmaceuticals, Inc. para o desenvolvimento do ADX-1612, que inibe a chaperona proteica para o tratamento de doenças inflamatórias. A empresa era anteriormente conhecida como Aldexa Therapeutics, Inc. e mudou o seu nome para Aldeyra Therapeutics, Inc. em março de 2014. A Aldeyra Therapeutics, Inc. foi constituída em 2004 e tem sede em Lexington, Massachusetts.

Nome
Aldeyra Therapeutics
CEO
Todd C. Brady
Sede Lexington, ma
EUA
Site
Setor
Cuidados de saúde
Indústria
Biotecnologia
Entrada em bolsa
02/05/2014
Colaboradores 6

Símbolos de ticker

Bolsa Símbolo
NASDAQ
ALDX
Frankfurt
137.F
Düsseldorf
137.DU
München
137.MU
🍪

Parqet  utiliza cookies. Saber mais